Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 3/20 | 0.36 |
| ▸ | BLM | P54132 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349926 | 1.00 | AURKA (0.44) | AURKAAURKBTTRCYP1A2CTRB1 | |
| SCHEMBL28048029 | 0.90 | AURKA (0.42) | AURKAAURKBTTRCYP1A2CTRB1 | |
| SCHEMBL6135405 | 0.88 | AURKA (0.40) | AURKAAURKBTTRCYP1A2CTRB1 | |
| SCHEMBL6687050 | 0.85 | CTRB1 (0.43) | AURKAAURKBTTRCYP1A2CTRB1 | |
| SCHEMBL10001904 | 0.84 | AURKA (0.47) | AURKAAURKBTTRCYP1A2CTRB1 | |
| SCHEMBL18315988 | 0.83 | CTRB1 (0.42) | AURKAAURKBTTRCYP1A2CTRB1 | |
| SCHEMBL18315990 | 0.83 | CTRB1 (0.42) | AURKAAURKBCYP1A2CTRB1ALDH1A1 | |
| SCHEMBL11528264 | 0.82 | AURKA (0.46) | AURKAAURKBTTRCYP1A2CTRB1 | |
| SCHEMBL6535450 | 0.81 | AURKA (0.38) | AURKAAURKBTTRCYP1A2CTRB1 | |
| SCHEMBL17121328 | 0.81 | AURKA (0.56) | AURKAAURKBTTRCYP1A2CTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012010851-A1 | CAPILLARY ELECTROPHORESIS OF CARBOHYDRATES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-01-26 | — | — | WO | claimed |
| EP-4363847-B1 | INTEGRATED METHOD FOR URINARY PROSTATE SPECIFIC ANTIGEN N-GLYCOSYLATION PROFILING BY CAPILLARY ELECTROPHORESIS | PANNON EGYETEM (HU) | 2025-01-15 | — | — | EP | disclosed |
| US-20240272117-A1 | INTEGRATED METHOD FOR URINARY PROSTATE SPECIFIC ANTIGEN N-GLYCOSYLATION PROFILING BY CAPILLARY ELECTROPHORESIS | PANNON EGYETEM (HU) | 2024-08-15 | — | — | US | disclosed |
| CN-109923407-A | Sugar chain analytic method | 株式会社岛津制作所 | 2019-06-21 | — | — | CN | disclosed |
| CN-101680014-B | Glycosylation of molecules | 奥克西雷恩英国有限公司 | 2018-09-28 | — | — | CN | disclosed |
| US-10052393-B2 | Multifunctional nanomaterials for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-08-21 | — | — | US | disclosed |
| CN-105579848-A | Method for the analysis of N-glycans attached to immunoglobulin G from human blood plasma and its use | GENOS D O O | 2016-05-11 | — | — | CN | disclosed |
| CN-102770765-B | Use 2-picoline borine as reductive agent reduction amination and analyze carbohydrate | Leiden University Hospital under the name Leiden University Medical Center (NL) | 2016-02-10 | — | — | CN | disclosed |
| CN-105121471-A | Pertuzumab variants and evaluation thereof | HOFFMANN LA ROCHE | 2015-12-02 | — | — | CN | disclosed |
| CN-104379162-A | Methods and materials for treating Pompe's disease | OXYRANE UK LTD | 2015-02-25 | — | — | CN | disclosed |
| US-20140378831-A1 | MULTIFUNCTIONAL NANOMATERIALS FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240272117-A1 | INTEGRATED METHOD FOR URINARY PROSTATE SPECIFIC ANTIGEN N-GLYCOSYLATION PROFILING BY CAPILLARY ELECTROPHORESIS | KLK3, MAN2B2, ENGASE | AURKA 3540/4885AURKB 3980/4885TTR 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.